Fig. 1From: Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter studyMaximal Percent Change in the Sum of the Products of Perpendicular Diameters of Target Lesions (SPD) and Corresponding Best ResponsesBack to article page